home / stock / phvs / phvs quote
Last: | $22.60 |
---|---|
Change Percent: | -1.02% |
Open: | $23.77 |
Close: | $22.60 |
High: | $23.9 |
Low: | $22.475 |
Volume: | 55,487 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$22.6 | $23.77 | $22.6 | $23.9 | $22.475 | 55,487 | 05-03-2024 |
$23.53 | $24.685 | $23.53 | $25.5 | $23.49 | 78,777 | 05-02-2024 |
$24.57 | $24.01 | $24.57 | $25.16 | $23.16 | 114,135 | 05-01-2024 |
$24.59 | $23.25 | $24.59 | $25.2 | $23.25 | 67,926 | 04-30-2024 |
$23.45 | $23.35 | $23.45 | $24.15 | $22.55 | 49,577 | 04-29-2024 |
$23.35 | $22.56 | $23.35 | $25.44 | $22.2 | 85,067 | 04-26-2024 |
$22.77 | $20.74 | $22.77 | $24 | $19.59 | 82,367 | 04-25-2024 |
$21.25 | $21.45 | $21.25 | $22.715 | $21.02 | 34,153 | 04-24-2024 |
$21.29 | $20.85 | $21.29 | $24.2 | $20.54 | 88,778 | 04-23-2024 |
$20.87 | $19.5 | $20.87 | $20.87 | $17.57 | 50,601 | 04-22-2024 |
$19.16 | $18.05 | $19.16 | $20.02 | $18.05 | 133,811 | 04-19-2024 |
$18.42 | $21.19 | $18.42 | $21.19 | $18.325 | 69,471 | 04-18-2024 |
$21.2 | $21.36 | $21.2 | $21.58 | $20.725 | 327,306 | 04-17-2024 |
$21 | $20.26 | $21 | $21.4175 | $19.94 | 64,230 | 04-16-2024 |
$20.15 | $21.75 | $20.15 | $21.75 | $19.86 | 167,186 | 04-15-2024 |
$21.9 | $22.45 | $21.9 | $23.23 | $21.7101 | 10,915 | 04-12-2024 |
$22.31 | $23.94 | $22.31 | $24.27 | $21.92 | 78,123 | 04-11-2024 |
$22.27 | $22.8 | $22.27 | $22.99 | $21.49 | 155,582 | 04-10-2024 |
$23.14 | $22.75 | $23.14 | $23.37 | $22.3501 | 12,100 | 04-09-2024 |
$22.74 | $22.72 | $22.74 | $23.2899 | $22.06 | 64,228 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling End-of-Phase 2 meeti...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks Strengthened executive committee with hiring of D...
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral brad...